British Journal of Medical & Surgical Urology
Volume 2, Issue 6 , Pages 219-223 , November 2009

Clarification of NICE guidance on prostate cancer

  • David E. Neal

      Affiliations

    • Uro-Oncology (S4), BOX 279, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, United Kingdom
    • Corresponding Author InformationCorresponding author.
    • ,
  • John McLoughlin

      Affiliations

    • Addenbrooke's and West Suffolk Hospitals, United Kingdom
    • ,
  • John B. Anderson

      Affiliations

    • Royal Hallamshire Hospital, Sheffield, United Kingdom
    • ,
  • Derek P. Fawcett

      Affiliations

    • British Association of Urological Surgeons, United Kingdom
    • ,
  • Roger C. Kockelbergh

      Affiliations

    • Department of Urology, University Hospitals of Leicester NHS Trust, United Kingdom

References 

  1. NICE . Prostate cancer. 2009;http://guidanceniceorguk/CG58
  2. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100(August):1144–1154
  3. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(March):1320–1328
  4. Neal DE, Donovan JL, Martin RM, Hamdy FC. Screening for prostate cancer remains controversial. Lancet. 2009;(August):
  5. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(March):316–321
  6. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol. 2009;6(August):429–439
  7. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448(August):595–599
  8. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci. 2008;121(April):957–968
  9. Massie CE, Adryan B, Barbosa-Morais NL, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 2007;8(September):871–878
  10. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(May):787–790
  11. Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(August):3742–3748
  12. Donovan J, Mills N, Smith M, et al. Quality improvement report - Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Br Med J. 2002;325(October):766–769
  13. Parker C, Clarke N, Logue J, et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol). 2007;19(April):167–171
  14. Cochrane AL. Random reflections on health services. London: RSM Press; 2007;
  15. NICE . Prostate cancer: diagnosis and treatment, vol. 2009, National Collaborating Centre for Cancer. 2008;http://www.nice.org.uk/nicemedia/pdf/CG58FullGuideline.pdf
  16. Wilt TJ. Commentary: controversies in NICE guidance on prostate cancer. BMJ. 2008;336(March):612–614
  17. NHS. Urology Informed Decision Making Project. 2009 [cited; Available from:].
  18. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95(July):281–286
  19. Neal DE. Can we accurately identify men with low risk prostate cancer?. J Urol. 2008;180(October):1217–1218
  20. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(June):2388–2399
  21. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007;99(April):526–532
  22. Cuzick J, Fisher G, Kattan MW, et al. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer. 2006;95(November):1186–1194
  23. Loberg RD, Fielhauer JR, Pienta BA, et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology. 2003;62(Suppl. 1 (December)):128–133
  24. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(April):1596–1605
  25. Vickers AJ, Savage C, O’Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27(January):398–403
  26. O’Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol. 2009;27(August):3591–3597
  27. Metcalfe C, Tilling K, Davis M, et al. Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. Br J Cancer. 2009;101(August):390–394
  28. Loeb S. Prostate cancer: is PSA velocity useful?. Nat Rev Urol. 2009;6(June):305–306
  29. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2006;CD006250
  30. NICE . Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk. 2009;http://wwwniceorguk/guidance/indexjsp?action=byID&r=true&o=11621

PII: S1875-9742(09)00133-5

doi: 10.1016/j.bjmsu.2009.09.001

British Journal of Medical & Surgical Urology
Volume 2, Issue 6 , Pages 219-223 , November 2009

Article Tools